NCT02491632 2026-03-18
Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer
M.D. Anderson Cancer Center
Phase 2/3 Active not recruiting
Clinical Trials
25 trialsNCT07095452 2026-03-16
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
AbbVie
Phase 2/3 Recruiting
NCT07428369 2026-02-23
LINKER-MM8
Regeneron Pharmaceuticals
Phase 2/3 Not yet recruiting
NCT07213375 2026-01-07
DEXTER
Rigshospitalet, Denmark
Phase 2/3 Recruiting
NCT03117751 2025-12-05
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2/3 Active not recruiting
NCT06855810 2025-08-26
CCCG-TALL-2025
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3 Recruiting
NCT06882057 2025-08-26
CCCG-LR-B-ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3 Recruiting
NCT04862585 2025-08-20
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
Ohio State University Comprehensive Cancer Center
Phase 2/3 Completed
NCT05096663 2025-05-15
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2/3 Active not recruiting
NCT04513639 2025-03-20
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
Oslo University Hospital
Phase 2/3 Recruiting
NCT06879379 2025-03-17
KPD Consolidation After ASCT in NDMM Patients
Peking University People's Hospital
Phase 2/3 Recruiting
NCT01228331 2024-12-11
Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL
Universitätsklinikum Hamburg-Eppendorf
Phase 2/3 Completed
NCT02416388 2024-08-07
BIG-1
University Hospital, Angers
Phase 2/3 Recruiting
NCT04061512 2024-05-10
RAINBOW
University College, London
Phase 2/3 Recruiting
NCT03759093 2023-09-06
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
Phase 2/3 Unknown
NCT00199108 2022-08-18
Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt
Goethe University
Phase 2/3 Completed
NCT03668639 2021-12-14
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
Odense University Hospital
Phase 2/3 Unknown
NCT00720109 2020-04-13
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT00038090 2018-10-31
Thalidomide-Dexamethasone for Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2/3 Completed
NCT03564704 2018-06-21
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT03553238 2018-06-12
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT02419118 2017-11-07
DARA
Vejle Hospital
Phase 2/3 Completed
NCT00861250 2016-06-17
Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT
Tampere University Hospital
Phase 2/3 Completed
NCT00934739 2015-02-25
A Study of High-Risk Oral Cavity Cancer
National Health Research Institutes, Taiwan
Phase 2/3 Terminated
NCT00002499 2013-09-20
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2/3 Unknown